STAT1 and posterior cortical atrophy: For instance, the combination of classical therapeutic drugs with highly ARTD8 or DTX3L-specific inhibitors and drugs specifically targeting STAT1 or the macrodomains of ARTD9 might provide a novel therapeutic strategy to increase the sensitivity of PCa cells towards classical therapy, and thus pave the way to develop novel personalized therapeutic strategies for patients suffering from aggressive PCa.